Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of LVRNA009 mRNA vaccine for prevention of COVID-19 in adults
PACTR202205492711803Phase 3Completed
- Sponsor
- AIM Vaccine Co., Ltd.
- Start
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing LVRNA009 with Placebo (2 arms). Primary endpoint: Incidence density of first symptomatic virologically confirmed COVID-19. Started Nov 2022; status: completed.
02
Drugs
LVRNA009
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202205492711803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202205492711803.